Defense Threat Reduction Agency; J9-Chemical and Biological Technologies Department; Translational Medical Division; Fort Belvoir, VA USA.
Hum Vaccin Immunother. 2013 Jul;9(7):1591-7. doi: 10.4161/hv.24063. Epub 2013 Feb 21.
The Defense Threat Reduction Agency's Joint Science and Technology Office manages the Chemical and Biological Defense Program's Science and Technology portfolio. The Joint Science and Technology Office's mission is to invest in transformational ideas, innovative people and actionable technology development for Chemical and Biological Defense solutions, with the primary goal to deliver Science and Technology products and capabilities to the warfighter and civilian population that outpace the threat. This commentary focuses on one thrust area within this mission: the Vaccine program of the Joint Science and Technology Office's Translational Medical Division. Here, we will describe candidate vaccines currently in the S&T pipeline, enabling technologies that should facilitate advanced development of these candidates into FDA licensed vaccines, and how the ever-changing biological threat landscape impacts the future of biodefense vaccines.
国防威胁降低局的联合科学技术办公室管理着化学和生物防御计划的科学和技术组合。联合科学技术办公室的任务是投资于变革性的想法、创新的人才和可操作的技术开发，以实现化学和生物防御解决方案，其主要目标是为作战人员和民用人口提供超越威胁的科学和技术产品和能力。本评论集中讨论了这一任务中的一个重点领域：联合科学技术办公室转化医学分部的疫苗计划。在这里，我们将描述目前处于 S&T 管道中的候选疫苗、使这些候选疫苗能够进入 FDA 许可疫苗的先进开发的使能技术，以及不断变化的生物威胁格局如何影响生物防御疫苗的未来。
